Koers Cerevel Therapeutics Holdings, Inc.
Aandelen
CERE
US15678U1280
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
42,16 USD | -0,33% | -0,94% | -0,59% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 7,71 mld. 7,15 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -456 mln. -423 mln. | Nettowinst (verlies) 2025 * | -551 mln. -512 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 619 mln. 575 mln. | Nettoliquiditeiten 2025 * | 690 mln. 641 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-17
x | K/w-verhouding 2025 * |
-15
x | Werknemers | 334 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 42,27% |
Recentste transcriptie over Cerevel Therapeutics Holdings, Inc.
1 dag | -0,35% | ||
1 week | -0,94% | ||
Lopende maand | -1,31% | ||
1 maand | +0,09% | ||
3 maanden | -2,20% | ||
6 maanden | +74,03% | ||
Lopend jaar | -0,59% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ronald Renaud
CEO | Chief Executive Officer | 55 | 12-06-23 |
Director of Finance/CFO | 42 | 15-05-23 | |
N. Coles
CHM | Chairman | 63 | 01-12-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 63 | 01-06-19 | |
Douglas Giordano
BRD | Director/Board Member | 61 | 01-09-18 |
Ruth McKernan
BRD | Director/Board Member | 66 | 04-12-20 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.10% | 2 M€ | -.--% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
10-05-24 | 42,16 | -0,33% | 411 643 |
09-05-24 | 42,3 | +0,57% | 1 295 038 |
08-05-24 | 42,06 | -0,47% | 1 120 947 |
07-05-24 | 42,26 | -0,61% | 878 973 |
06-05-24 | 42,52 | -0,07% | 676 474 |
uitgestelde koers Nasdaq, 10 mei 2024 om 21:59 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,59% | 7,71 mld. | |
+4,01% | 108 mld. | |
+11,03% | 104 mld. | |
+1,28% | 22,33 mld. | |
-13,22% | 22,19 mld. | |
-7,05% | 18,69 mld. | |
-38,36% | 17,74 mld. | |
-10,60% | 17,64 mld. | |
+3,78% | 14,05 mld. | |
+36,73% | 12,51 mld. |